The Swedish-American Life Science Summit in Stockholm, August 20-22

Life Sciences in a Rapidly Evolving World Economy

Fourth Life Science Summit Features Cutting Edge Research, Leading Investors and Entrepreneurs and Corporate Leaders

The fourth annual Swedish-American Life Science Summit (SALSS) opens in Stockholm, Sweden on August 20, 2008. The intense and exclusive two-day program (Aug 20-22) takes place against a backdrop of major scientific breakthroughs and a volatile business economy.

"It is our hope and ambition that the summit will serve to increase the amount of cross-border business between the United States, the largest healthcare market in the world, and Sweden, one of the most important Life Science industry centers in Europe, and extend that footprint to other key global centers," says Barbro C. Ehnbom, founder and chairman of SALSS. Ms. Ehnbom has held top level positions on Wall Street and in the pharmaceutical industry and has a long and extensive experience in Swedish-American investment banking.

Against the uncertainties of the life science business and the unpredictable economic climate, the need for collaborative problem solving is greater than ever. The Fourth SALSS, which features the leaders of the industry in both Sweden and the U.S., is an ideal and effective forum."

Key participants at this year's summit include:

--  Jacob Wallenberg, CEO, Investor AB
--  Andy Davies, Director, Business Development, Amgen
--  Dr. William Haseltine, Chairman, Haseltine Global Health
--  Dr. Doug Fambrough, Partner, Oxford Biosciences
--  Niklas Prager, CEO, Pfizer AB
--  Peter Kash, Chairman, Two River Group Holdings
--  Glen Giovanetti, Head of Life Sciences, Ernst & Young
--  Robert Charpentier, CEO, Kaupthing Bank
--  Professor Mathias Uhlén, Royal Institute of Technology in Stockholm
--  William Gedale, Managing Partner, NGN Capital
--  Professor Hans Wigzell, Karolinska Development
--  Dr. Ellen Strahlman, Sr. Vice President & Chief Medical Officer of
    GlaxoSmithKline